HRS 6208
Alternative Names: HRS-6208Latest Information Update: 07 Feb 2025
Price :
$50 *
At a glance
- Originator Shandong Suncadia Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Dec 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (unspecified route) (NCT06727812)
- 11 Dec 2024 Shandong Suncadia Medicine plans phase-I trial for Solid tumours (Late-stage disease, Monotherapy, Metastatic disease, Inoperable/Unresectable) in China (PO) in December 2024 (NCT06727812) (CTR20244522)
- 11 Dec 2024 Preclinical trials in Solid tumours in China (Unspecified) before December 2024 (NCT06727812) (CTR20244522)